Petros Pharmaceuticals Inc. (PTPI) News

Petros Pharmaceuticals Inc. (PTPI): $0.28

0.01 (-2.58%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add PTPI to Watchlist
Sign Up

Filter PTPI News Items

PTPI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PTPI News From Around the Web

Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in discussions with third-party technology partnersNEW YORK, ...

Yahoo | October 30, 2023

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding ...

Yahoo | October 19, 2023

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication ...

Yahoo | October 4, 2023

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief ...

Yahoo | September 28, 2023

Petros Pharmaceuticals Provides Letter to Shareholders

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:

Yahoo | September 11, 2023

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/ Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

Yahoo | September 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!

William White on InvestorPlace | July 14, 2023

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status.

Yahoo | July 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!